Correct according to whom? If you want to choose only one metric quality adjusted life years is likely the best one.
While OS may be your goal that's not the primary endpoint of screening programs.
Some examples of why OS is limited: breast lumpectomy vs mastectomy and systemic therapy or polypectomy vs neoadjuvant therapy and colonic resection are both associated with very high morbidity that is very important to patients. The vast majority of patients care about quality of life.
> "Sufficiently powered" is relative to what size of effect you want to detect--which you haven't specified, so I'm not sure how you can make the assertion that none of the studies are sufficiently powered.
We do not expect any one screening program to have a large change on overall survival because there are many ways to die, very few studies are powered to detect the small differences expected. The reference below does some modeling and discusses cancer-specific vs all-cause mortality for your perusal.
https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.2476
> These outcomes ignore negative effects of screening on people who don't have cancer, which is why I'm not interested in them.
See morbidity discussion around delayed diagnosis above.
> And yes, there are negative effects, and no, they are not negligible.
As you're choosing to limit the discussion to overall survival, do you have any data to support the claim that screening has more than a negligible negative effect?
There is a better argument to be made for other harms of screening like cost and stress but if we want to discuss these negative effects of screening we also have to step back from overall survival and discuss morbidity benefits.
ETA:
> 2) that I'm misinterpreting something, given that I didn't really offer any interpretation at all.
This is your interpretation, and is an incorrect one:
> The evidence in favor of mass screening programs in the hope of early detection is actually weak to non-existent [1].
The evidence you cite says nothing about early detection and treatment paradigms.